Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Phase 1 Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Anti-PD-1 in Patients With Advanced Solid Tumors
Sponsor: Alcura Health España SA
This PHASE1 trial investigates Advanced Solid Tumor and is currently actively recruiting participants. Alcura Health España SA leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Mar 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alcura Health España SA
- Anapharm Bioanalytics
- Biotrial
- CTI Laboratory Services Spain
- Centro de Investigación del Cáncer Universidad de Salamanca
- Certara
- Clinigen, Inc.
- Evidenze
- HistoOne
- Oncomatryx Biopharma S.L.
- Opthimapharm
- TFS Health Science
For direct contact, visit the study record on ClinicalTrials.gov .